WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Laurence Chen
Patent Agent
Patents and Innovations
San Francisco
laurence.chen@wsgr.com

D212-497-7743

Download vCard
Open PDF

Dr. Laurence Chen is a patent agent in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm’s patents and innovations practice. His technical expertise spans a variety of fields including biological engineering, gene editing, cancer immunotherapy, and multi-omic technologies.

Prior to joining the firm, Laurence completed his doctorate degree in chemical engineering at the University of California, Los Angeles. His doctoral research leveraged synthetic biology, protein engineering, cell engineering, and multi-omics in developing CAR-T cells for next-generation cancer immunotherapies. His graduate work has resulted in multiple scientific publications and he is also a co-inventor on multiple patent applications.

Experience

Dr. Laurence Chen is a patent agent in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm’s patents and innovations practice. His technical expertise spans a variety of fields including biological engineering, gene editing, cancer immunotherapy, and multi-omic technologies.

Prior to joining the firm, Laurence completed his doctorate degree in chemical engineering at the University of California, Los Angeles. His doctoral research leveraged synthetic biology, protein engineering, cell engineering, and multi-omics in developing CAR-T cells for next-generation cancer immunotherapies. His graduate work has resulted in multiple scientific publications and he is also a co-inventor on multiple patent applications.

Education
  • Ph.D., Chemical Engineering, University of California, Los Angeles, 2022
  • B.S., Bioengineering: Biotechnology, University of California, San Diego, 2016
Admissions
  • U.S. Patent and Trademark Office
Credentials
Education
  • Ph.D., Chemical Engineering, University of California, Los Angeles, 2022
  • B.S., Bioengineering: Biotechnology, University of California, San Diego, 2016
Admissions
  • U.S. Patent and Trademark Office

Select Publications

  • Co-lead author with X. Chen and Y.Y. Chen, “Rational protein design yields a CD20 CAR with superior antitumor efficacy compared to CD19 CAR,” Cancer Immunology Research, 2022
  • Co-author with A. Lakhani, Y.Y. Chen, and J.O. Park, “Extracellular domains of CARs reprogramme T cell metabolism without antigen stimulation,” Nature Metabolism, 2024
  • Co-lead author with A.J. Hou and Y.Y. Chen, “Navigating CAR-T cells through the solid-tumour microenvironment,” Nature Reviews Drug Discovery, 2021
  • Lead author with Y.Y. Chen, “Bacteria recycle tumour waste to fuel immune cells,” Nature (News & Views), 2021
  • Lead author with Y.Y. Chen, “Outsmarting and outmuscling cancer cells with synthetic and systems immunology,” Current Opinion in Biotechnology, 2019
Insights

Select Publications

  • Co-lead author with X. Chen and Y.Y. Chen, “Rational protein design yields a CD20 CAR with superior antitumor efficacy compared to CD19 CAR,” Cancer Immunology Research, 2022
  • Co-author with A. Lakhani, Y.Y. Chen, and J.O. Park, “Extracellular domains of CARs reprogramme T cell metabolism without antigen stimulation,” Nature Metabolism, 2024
  • Co-lead author with A.J. Hou and Y.Y. Chen, “Navigating CAR-T cells through the solid-tumour microenvironment,” Nature Reviews Drug Discovery, 2021
  • Lead author with Y.Y. Chen, “Bacteria recycle tumour waste to fuel immune cells,” Nature (News & Views), 2021
  • Lead author with Y.Y. Chen, “Outsmarting and outmuscling cancer cells with synthetic and systems immunology,” Current Opinion in Biotechnology, 2019

Biological Sciences and Biotechnology

  • Antibody
  • Antigen presentation
  • Biochemical assays
  • Biochemistry
  • Biologics
  • Cancer biology
  • Cancer therapeutics
  • CAR-T cells
  • Cell biology
  • Cell culture products
  • Cell therapy
  • Cellular biology
  • Cellular immunology
  • Immuno-oncology
  • Immunobiology
  • Immunology
  • Molecular biology
  • Molecular genetics
  • PCR
  • T cell biology
  • T cell immunology

Therapeutics and Drug Discovery

  • CRISPR
  • Gene editing
  • Gene therapy
  • Immunotherapy targets
  • Peptide therapeutics

Diagnostics and Medical Devices

  • Biomedical engineering

Chemistry and Material Science

  • Protein engineering

Engineering and Technology

  • 3D bioprinting

Genomics and Data Analysis

  • Bioinformatics algorithms
  • Computational biology
  • Next-generation sequencing
  • Single-cell sequencing

Miscellaneous

  • Cancer
  • Engineered foods
  • Food science
Technical Fluency

Biological Sciences and Biotechnology

  • Antibody
  • Antigen presentation
  • Biochemical assays
  • Biochemistry
  • Biologics
  • Cancer biology
  • Cancer therapeutics
  • CAR-T cells
  • Cell biology
  • Cell culture products
  • Cell therapy
  • Cellular biology
  • Cellular immunology
  • Immuno-oncology
  • Immunobiology
  • Immunology
  • Molecular biology
  • Molecular genetics
  • PCR
  • T cell biology
  • T cell immunology

Therapeutics and Drug Discovery

  • CRISPR
  • Gene editing
  • Gene therapy
  • Immunotherapy targets
  • Peptide therapeutics

Diagnostics and Medical Devices

  • Biomedical engineering

Chemistry and Material Science

  • Protein engineering

Engineering and Technology

  • 3D bioprinting

Genomics and Data Analysis

  • Bioinformatics algorithms
  • Computational biology
  • Next-generation sequencing
  • Single-cell sequencing

Miscellaneous

  • Cancer
  • Engineered foods
  • Food science
Focus Areas
  • Biotech
  • Clean Energy
  • FoodTech and AgTech
  • Intellectual Property
  • Life Sciences
  • Medical Devices
  • Patents and Innovations
Recent Insights
Client Highlights
Firm Advises MARAbio Systems on IP Matters Related to $19 Million Series A
On October 8, 2024, MARAbio Systems, Inc., a precision immunology company whose mission is to detect, treat, and prevent Maternal Autoantibody Related Autism, announced that it has closed $19 million in Series A financing. The round, which was led by investment management firm MAK Capital One, LLC, is open to new investors through year-end 2024. Wilson Sonsini Goodrich & Rosati advised MARAbio on intellectual property matters related to the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Pascal on IP Matters Related to $8 Million Seed Round
On May 8, 2024, Pascal, a start-up developing high-efficiency climate-friendly heat pumps, air conditioners, and refrigerators based on solid refrigerants, introduced its novel technology and announced it has raised an $8 million seed round led by Engine Ventures, with Khosla Ventures and previous investor Blindspot Ventures participating. The funding will be used to productize Pascal’s low pressure, solid refrigerant-based system, conforming to commercial HVAC specifications. The company will also use the capital to expand its Boston-based team of mechanical engineers, chemists, and material scientists. Pascal launched from the Mason Group at Harvard University, a research group led by Jarad Mason in the Department of Chemistry and Chemical Biology that applies the tools of coordination chemistry, materials science, and nanotechnology to design materials that address science challenges in energy and medicine.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.